Linzess sales strength, apraglutide Phase III catalyst, FY2026 guidance and $5.37 target—read now for key upside drivers.
Q1 2026 Earnings Call May 11, 2026 8:00 PM EDTCompany ParticipantsRobert Rethy - Head of the Investor Relations & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results